|
|
Volumn 498, Issue 7455, 2013, Pages S8-S9
|
|
Drug development: Target practice
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CD135 ANTIGEN;
FLT3 PROTEIN, HUMAN;
PROTEIN KINASE INHIBITOR;
ACUTE GRANULOCYTIC LEUKEMIA;
ACUTE LYMPHOBLASTIC LEUKEMIA;
ADULT;
ARTICLE;
CHILD;
CHRONIC LYMPHATIC LEUKEMIA;
CHRONIC MYELOID LEUKEMIA;
CLINICAL TRIAL (TOPIC);
DRUG ANTAGONISM;
DRUG DEVELOPMENT;
GENETICS;
HUMAN;
LEUKEMIA;
MOLECULARLY TARGETED THERAPY;
SURVIVAL RATE;
TREATMENT OUTCOME;
ADULT;
ANTINEOPLASTIC AGENTS;
CHILD;
CLINICAL TRIALS AS TOPIC;
DRUG DISCOVERY;
FMS-LIKE TYROSINE KINASE 3;
HUMANS;
LEUKEMIA;
LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;
LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;
LEUKEMIA, MYELOID, ACUTE;
MOLECULAR TARGETED THERAPY;
PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;
PROTEIN KINASE INHIBITORS;
SURVIVAL RATE;
TREATMENT OUTCOME;
|
|
EID: 84880153148
PISSN: 00280836
EISSN: None
Source Type: Journal
DOI: 10.1038/498S8a Document Type: Article |
|
Times cited : (8)
|
|
References (5)
|
